- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01310621
Comparison Of Surfactant Lung Lavage With Standard Care In The Treatment Of Meconium Aspiration Syndrome (Sur-Lu-Lav)
Surfactant Lung Lavage Versus Standard Care In The Treatment Of Meconium Aspiration Syndrome- A Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Meconium is an odourless, thick, blackish green material first demonstrable in the foetal intestinal tract during the third month of gestation. Approximately 10-15% of deliveries are complicated by the passage of meconium around the time of delivery. The risk of meconium stained amniotic fluid (MSAF) is strongly correlated with gestational age. An adverse intrauterine environment with resultant foetal asphyxia is proposed as the most common explanation for MSAF.
Aspiration of meconium into the tracheo-bronchial tree with the onset of respiration results in meconium aspiration syndrome (MAS). MAS is defined as respiratory distress with compatible chest x-ray finding in an infant born through MSAF whose symptoms cannot be otherwise explained. Despite current interventions such as intubation with tracheal suction, it is estimated that 5-20 % of infants born through MSAF develop MAS. It represents a leading cause of perinatal morbidity. Approximately 50% of the infants with MAS require mechanical ventilation; 15%-30% develop pulmonary air leaks and 5%-12% die.
The pathophysiology of meconium aspiration syndrome includes airway obstruction, surfactant inactivation, inflammation and pulmonary hypertension. Meconium itself inactivates the surfactant in the alveoli and its presence also causes secondary surfactant deficiency as meconium is toxic to type 2 alveolar cells which secrete surfactant. There is no specific treatment recommended for meconium aspiration syndrome .Treatment for MAS is generally supportive and includes supplemental oxygen as needed, assisted ventilation to maintain lung volume and improve gas exchange, and circulatory support with volume resuscitation and vasopressor infusions to maintain adequate perfusion. Successful treatment of meconium aspiration relies on effective meconium removal without inactivating or washing out surfactant, followed by appropriate ventilator care.
Surfactant replacement in neonates with severe meconium aspiration syndrome has been shown to improve oxygenation and reduce the severity of respiratory failure, air leaks and need for extracorporeal membrane oxygenation.
Surfactant replacement alone does not remove the meconium present in the airways and hence multiple doses may be required. Therefore an effective strategy to improve outcome in neonates with MAS needs to not only remove meconium but also retain the surfactant for adequate lung expansion and function.
Lung lavage using diluted surfactant has recently been shown to be an alternative to bolus therapy in treating MAS. This has advantage of removing surfactant inhibitors from alveolar space, in addition to augmenting surfactant concentration in alveolar space. Initial pilot case series using surfactant lung lavage have shown promise and there is a need to systematically study this in a RCT. The same has also been expressed in the literature on this subject. Hence the purpose of this prospective randomized controlled trial is to compare the efficacy of surfactant lung lavage over standard therapy in the treatment of meconium aspiration syndrome.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110001
- Kalawati Saran children's Hospital, Lady Hardinge Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestation age ≥ 37 week
- Cephalic presentation
- Singleton pregnancy
- Presence of meconium stained amniotic fluid or staining of meconium in skin,umbilical cord or nails.
- Non vigorous babies
- Presence of respiratory distress(Downes score ≥4)
- Presence of meconium below vocal cords or chest x ray suggestive of meconium aspiration
- Age < 2 hours
Exclusion Criteria:
- Major congenital malformations
- Congenital heart disease
- Hydrops fetalis
- Air leaks
- Pulmonary hemorrhage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No Lavage
Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward.
The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
|
|
Experimental: Surfactant Lavage
The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds.
Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine.
The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube.
Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value.
The same shall be resumed once prelavage oxygen saturation has been restored.
The infant's bed will now be moved back to horizontal position.
Once the neonate is STABLE, suctioning will be again repeated.
The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
duration of oxygen therapy in hours
Time Frame: till discharge or death
|
The duration of oxygen therapy, mode of delivery, FiO2 and flow rate will be documented hourly within first 2 hours before lavage and in post lavage- hourly up to first 24 hours, 2 hourly up to 72 hours and 4 hourly thereafter till the cessation of oxygen therapy
|
till discharge or death
|
Severity of respiratory distress
Time Frame: till discharge or death
|
The severity of respiratory distress will be assessed using Downe's Score.
These parameters will be documented hourly within first 2 hours before lavage and in post lavage hourly up to first 24 hours, 2 hourly up to 72 hours and 4 hourly thereafter till the cessation of respiratory distress
|
till discharge or death
|
need for mechanical ventilation
Time Frame: till discharge or death
|
The babies will be assessed for the need for mechanical ventilation as per standard unit protocols.
|
till discharge or death
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of mechanical ventilation
Time Frame: till discharge or death
|
Total duration of mechanical ventilation, mode and ventilator parameters are noted till the baby is on mechanical ventilation.
|
till discharge or death
|
Complications
Time Frame: till discharge
|
Incidence of PPHN by Echocardiography and Pneumothorax by transillumination confirmed by chest x-ray.
|
till discharge
|
Incidence of sepsis
Time Frame: till discharge
|
Incidence of sepsis defined as -
Sepsis Screen
|
till discharge
|
Mortality
Time Frame: till discharge
|
till discharge
|
|
Duration of Hospital stay
Time Frame: till discharge
|
till discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sushma Nangia, MBBS, MD, DM, Lady Hardinge Medical College, New Delhi, India
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LHMC/2011/Sur-Lu-Lav
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meconium Aspiration Syndrome
-
Ma JuanCompletedNeonatal Meconium AspirationChina
-
Windtree TherapeuticsTerminatedMeconium AspirationUnited States
-
The Hospital for Sick ChildrenUnknownMeconium Aspiration SyndromeCanada
-
The University of Texas Health Science Center,...Memorial Hermann HospitalCompletedSepsis | Persistent Fetal Circulation Syndrome | Diaphragmatic Hernia | Meconium AspirationUnited States
-
Lady Hardinge Medical CollegeCompletedMeconium Aspiration SyndromeIndia
-
St. Louis UniversityAmerican Academy of PediatricsWithdrawnMeconium Aspiration Syndrome
-
Zekai Tahir Burak Women's Health Research and Education...CompletedMeconium Aspiration SyndromeTurkey
-
Lady Hardinge Medical CollegeCompletedMeconium Aspiration SyndromeIndia
-
Poznan University of Medical SciencesCompletedMeconium Aspiration SyndromePoland
-
Seoul National University HospitalRecruitingRespiratory Distress Syndrome in Premature Infant | Meconium Obstruction of PrematurityKorea, Republic of
Clinical Trials on Bovine surfactant
-
Lawson Health Research InstituteLondon Health Sciences CentreCompleted
-
The Hospital for Sick ChildrenUnknownMeconium Aspiration SyndromeCanada
-
Lady Hardinge Medical CollegeRecruitingMeconium Aspiration Syndrome | Surfactant DysfunctionIndia
-
Indiana UniversityBLES Biochemicals Inc.Recruiting
-
Cairo UniversityCompleted
-
University Hospital PadovaCompletedRespiratory Distress Syndrome, NewbornItaly
-
Biosurf LLC.Active, not recruitingARDS Due to COVID-19Russian Federation
-
Hamilton Health Sciences CorporationTerminatedHyaline Membrane DiseaseCanada
-
University of Padova, School of Dental MedicineGeistlich Pharma AGCompleted
-
Ege UniversityCompleted